{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:26Z","timestamp":1791245186200,"version":"4.1.0"},"reference-count":177,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The introduction of novel oncologic therapies, including targeted agents, immunotherapies, and antibody\u2013drug conjugates, has transformed the therapeutic landscape of cancer care. This evolution has resulted in a dual clinical scenario; while survival outcomes have markedly improved, leading to a growing population of long-term cancer survivors, an increasing incidence of previously unrecognized treatment-related toxicities has emerged. Among these, cardiovascular adverse events represent some of the most prevalent and clinically significant complications observed in both conventional chemotherapy and modern therapeutic regimens. Cardiotoxicity has become a major concern, with the potential to adversely affect not only cardiovascular health but also the continuity and efficacy of oncologic treatments, thereby impacting overall survival. This opinion paper synthesizes current evidence, identifies critical gaps in knowledge, and advocates for a multidisciplinary, evidence-based framework to guide the prevention, early detection, and optimal management of cardiotoxicity associated with anticancer therapies.<\/jats:p>","DOI":"10.3390\/ph18091399","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:12:44Z","timestamp":1758121964000},"page":"1399","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0813-3126","authenticated-orcid":false,"given":"Giuliana","family":"Ciappina","sequence":"first","affiliation":[{"name":"Section of Experimental Medicine, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2946-0724","authenticated-orcid":false,"given":"Luigi","family":"Colarusso","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Maiorana","sequence":"additional","affiliation":[{"name":"School of Specialization in Medical Oncology, Department of Human Pathology \u201cG. Barresi\u201d, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-3855","authenticated-orcid":false,"given":"Alessandro","family":"Ottaiano","sequence":"additional","affiliation":[{"name":"Division of Innovative Therapies for Abdominal Metastases, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5920-4997","authenticated-orcid":false,"given":"Tindara","family":"Franchina","sequence":"additional","affiliation":[{"name":"Department of Human Pathology in Adult and Developmental Age \u2018Gaetano Barresi\u2019, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0924-2163","authenticated-orcid":false,"given":"Antonio","family":"Picone","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, AOU \u201cG. Martino\u201d Hospital, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Facchini","sequence":"additional","affiliation":[{"name":"Oncology Complex Unit, Santa Maria delle Grazie Hospital, Azienda Sanitaria Locale Napoli 2 Nord, 80078 Pozzuoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9244-8263","authenticated-orcid":false,"given":"Chiara","family":"Barraco","sequence":"additional","affiliation":[{"name":"Oncology Complex Unit, Santa Maria delle Grazie Hospital, Azienda Sanitaria Locale Napoli 2 Nord, 80078 Pozzuoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2878-3572","authenticated-orcid":false,"given":"Antonio","family":"Ieni","sequence":"additional","affiliation":[{"name":"Department of Human Pathology in Adult and Developmental Age \u2018Gaetano Barresi\u2019, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4706-870X","authenticated-orcid":false,"given":"Maurizio","family":"Cusm\u00e0 Piccione","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6908-4316","authenticated-orcid":false,"given":"Concetta","family":"Zito","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9837-9148","authenticated-orcid":false,"given":"Massimiliano","family":"Berretta","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"},{"name":"Division of Medical Oncology, AOU \u201cG. Martino\u201d Hospital, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.2147\/DDDT.S469331","article-title":"Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms, Clinical Management and Innovative Treatment","volume":"18","author":"Gao","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer Chemotherapy and beyond: Current Status, Drug Candidates, Associated Risks and Progress in Targeted Therapeutics","volume":"10","author":"Anand","year":"2023","journal-title":"Genes Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e000090","DOI":"10.1136\/bmjonc-2023-000090","article-title":"Cardiovascular Health: An Important Component of Cancer Survivorship","volume":"2","author":"Cleary","year":"2023","journal-title":"BMJ Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/postgradmedj-2016-134417","article-title":"Cardiovascular Disease in Cancer Survivors","volume":"93","author":"Okwuosa","year":"2017","journal-title":"Postgrad. Med. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaccao.2025.03.008","article-title":"Risk of Cardiovascular Disease in Cancer Survivors after Systemic Treatment: A Population-Based Cohort Study","volume":"7","author":"Mulder","year":"2025","journal-title":"JACC CardioOncology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A Population-Based Study of Cardiovascular Disease Mortality Risk in US Cancer Patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Morelli, M.B., Bongiovanni, C., Da Pra, S., Miano, C., Sacchi, F., Lauriola, M., and D\u2019Uva, G. (2022). Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.847012"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nrcardio.2015.133","article-title":"Erratum: Cardiotoxicity of Anticancer Treatments","volume":"12","author":"Ewer","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Zito, C., Manganaro, R., Ciappina, G., Spagnolo, C.C., Racanelli, V., Santarpia, M., Silvestris, N., and Carerj, S. (2022). Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do. Cancers, 14.","DOI":"10.3390\/cancers14215403"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijcard.2022.06.063","article-title":"Predictability of Cardiotoxicity: Experience of a Belgian Cardio-Oncology Clinic","volume":"363","author":"Jacobs","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-med-041316-090622","article-title":"Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention","volume":"69","author":"Narayan","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115361","DOI":"10.1016\/j.addr.2024.115361","article-title":"Navigating Cancer Therapy Induced Cardiotoxicity: From Pathophysiology to Treatment Innovations","volume":"211","author":"Jensen","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_14","first-page":"1132","article-title":"Cardiotoxicity of Chemotherapy and Targeted Agents","volume":"11","author":"Mudd","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1111\/febs.15583","article-title":"New Insights into the Activities and Toxicities of the Old Anticancer Drug Doxorubicin","volume":"288","author":"Qiao","year":"2021","journal-title":"FEBS J."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Cardinale, D., Iacopo, F., and Cipolla, C.M. (2020). Cardiotoxicity of Anthracyclines. Front. Cardiovasc. Med., 7.","DOI":"10.3389\/fcvm.2020.00026"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline Cardiotoxicity: An Update on Mechanisms, Monitoring and Prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00204-016-1759-y","article-title":"Pathways of Cardiac Toxicity: Comparison between Chemotherapeutic Drugs Doxorubicin and Mitoxantrone","volume":"90","author":"Damiani","year":"2016","journal-title":"Arch. Toxicol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Qiu, S., Zhou, T., Qiu, B., Zhang, Y., Zhou, Y., Yu, H., Zhang, J., Liu, L., Yuan, L., and Yang, G. (2021). Risk Factors for Anthracycline-Induced Cardiotoxicity. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.736854"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11912-018-0696-8","article-title":"Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity","volume":"20","author":"Chang","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/tpj.2015.63","article-title":"Polymorphisms of ABCC5 and NOS3 Genes Influence Doxorubicin Cardiotoxicity in Survivors of Childhood Acute Lymphoblastic Leukemia","volume":"16","author":"Krajinovic","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e018403","DOI":"10.1161\/JAHA.120.018403","article-title":"Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1161\/ATVBAHA.121.316697","article-title":"Cardiotoxicity of Cancer Treatments: Focus on Anthracycline Cardiomyopathy","volume":"41","author":"Nishi","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm.4017","article-title":"CaMKII Is a RIP3 Substrate Mediating Ischemia- and Oxidative Stress\u2013Induced Myocardial Necroptosis","volume":"22","author":"Zhang","year":"2016","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s11886-024-02131-5","article-title":"Inflammation in Chemotherapy-Induced Cardiotoxicity","volume":"26","author":"Hutchins","year":"2024","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCRESAHA.124.323800","article-title":"Mitochondrial Structure and Function in Human Heart Failure","volume":"135","author":"Hinton","year":"2024","journal-title":"Circ. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","article-title":"Regulated Cell Death Pathways in Doxorubicin-Induced Cardiotoxicity","volume":"12","author":"Christidi","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1039\/D1TB00551K","article-title":"The Role of Iron in Doxorubicin-Induced Cardiotoxicity: Recent Advances and Implication for Drug Delivery","volume":"9","author":"Qin","year":"2021","journal-title":"J. Mater. Chem. B"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e169756","DOI":"10.1172\/jci.insight.169756","article-title":"Mitochondria-Dependent Ferroptosis Plays a Pivotal Role in Doxorubicin Cardiotoxicity","volume":"8","author":"Tadokoro","year":"2023","journal-title":"JCI Insight"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Xie, S., Sun, Y., Zhao, X., Xiao, Y., Zhou, F., Lin, L., Wang, W., Lin, B., Wang, Z., and Fang, Z. (2024). An Update of the Molecular Mechanisms Underlying Anthracycline Induced Cardiotoxicity. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1406247"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Szponar, J., Ciechanski, E., Ciechanska, M., Dudka, J., and Mandziuk, S. (2024). Evolution of Theories on Doxorubicin-Induced Late Cardiotoxicity-Role of Topoisomerase. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252413567"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.semcdb.2019.05.011","article-title":"Wild Type- and Mutant P53 Proteins in Mitochondrial Dysfunction: Emerging Insights in Cancer Disease","volume":"98","author":"Blandino","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1038\/ncomms3308","article-title":"Cytosolic P53 Inhibits Parkin-Mediated Mitophagy and Promotes Mitochondrial Dysfunction in the Mouse Heart","volume":"4","author":"Hoshino","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_34","first-page":"1311","article-title":"Molecular Mechanisms of Anthracycline Cardiovascular Toxicity","volume":"135","author":"Narezkina","year":"2021","journal-title":"Clin. Sci. Lond. Engl. 1979"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Skaggs, C., Nick, S., Patricelli, C., Bond, L., Woods, K., Woodbury, L., Oxford, J.T., and Pu, X. (2023). Effects of Doxorubicin on Extracellular Matrix Regulation in Primary Cardiac Fibroblasts from Mice. BMC Res. Notes, 16.","DOI":"10.1186\/s13104-023-06621-7"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Bhutani, V., Varzideh, F., Wilson, S., Kansakar, U., Jankauskas, S., and Santulli, G. (2025). Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update. J. Cardiovasc. Dev. Dis., 12.","DOI":"10.3390\/jcdd12060207"},{"key":"ref_37","first-page":"1654","article-title":"American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy","volume":"19","author":"Amini","year":"2024","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_38","first-page":"7","article-title":"Mediastinal Irradiation and Valvular Heart Disease","volume":"8","author":"Patil","year":"2022","journal-title":"Cardio-Oncol. Lond. Engl."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Lestuzzi, C., Mascarin, M., Coassin, E., Canale, M.L., and Turazza, F. (2021). Cardiologic Long-Term Follow-Up of Patients Treated With Chest Radiotherapy: When and How?. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.671001"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e017454","DOI":"10.1161\/CIRCIMAGING.124.017454","article-title":"Imaging of the Acute and Chronic Cardiovascular Complications of Radiation Therapy","volume":"18","author":"Wilson","year":"2025","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s11886-023-01971-x","article-title":"Advances in Screening for Radiation-Associated Cardiotoxicity in Cancer Patients","volume":"25","author":"Schiffer","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/cvr\/cvaa222","article-title":"Cardiac Dysfunction in Cancer Patients: Beyond Direct Cardiomyocyte Damage of Anticancer Drugs: Novel Cardio-Oncology Insights from the Joint 2019 Meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart","volume":"116","author":"Tocchetti","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Jurczyk, M., Kr\u00f3l, M., Midro, A., Kurnik-\u0141ucka, M., Poniatowski, A., and Gil, K. (2021). Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194426"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.5306\/wjco.v11.i12.1008","article-title":"Fluoropyrimidine-Induced Cardiotoxicity","volume":"11","author":"Deac","year":"2020","journal-title":"World J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11864-020-0719-1","article-title":"Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines","volume":"21","author":"Shiga","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"de Moraes, F.C.A., de Almeida Barbosa, A.B., Sano, V.K.T., Kelly, F.A., and Burbano, R.M.R. (2024). Pharmacogenetics of DPYD and Treatment-Related Mortality on Fluoropyrimidine Chemotherapy for Cancer Patients: A Meta-Analysis and Trial Sequential Analysis. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12981-5"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC Scientific Document Group. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_48","first-page":"3","article-title":"Cardiovascular Safety of 5-Fluorouracil and Capecitabine in Colorectal Cancer Patients: Real-World Evidence","volume":"11","author":"Wong","year":"2025","journal-title":"Cardio-Oncol. Lond. Engl."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Duan, Y., Wang, Y., Lu, S., Zeng, M., Liu, L., Dai, Q., and Yin, R. (2024). Adverse Event Profile of Albumin-Bound Paclitaxel: A Real-World Pharmacovigilance Analysis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1448144"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e001849","DOI":"10.1136\/openhrt-2021-001849","article-title":"Cardiovascular Safety Profile of Taxanes and Vinca Alkaloids: 30 Years FDA Registry Experience","volume":"8","author":"Batra","year":"2021","journal-title":"Open Heart"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","article-title":"Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association","volume":"145","author":"Beavers","year":"2022","journal-title":"Circulation"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"107683","DOI":"10.1016\/j.carpath.2024.107683","article-title":"Doxorubicin-Related Cardiotoxicity: Review of Fundamental Pathways of Cardiovascular System Injury","volume":"73","author":"Avagimyan","year":"2024","journal-title":"Cardiovasc. Pathol. Off. J. Soc. Cardiovasc. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","article-title":"Anticancer Drug-Induced Cardiac Rhythm Disorders: Current Knowledge and Basic Underlying Mechanisms","volume":"189","author":"Alexandre","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/0036933019897347","article-title":"Cisplatin Related Cardiotoxicity\u2014Acute and Chronic Cardiovascular Morbidity in a Testicular Cancer Survivor","volume":"65","author":"Morrow","year":"2020","journal-title":"Scott. Med. J."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wang, H., Wang, Y., Li, J., He, Z., Boswell, S.A., Chung, M., You, F., and Han, S. (2023). Three Tyrosine Kinase Inhibitors Cause Cardiotoxicity by Inducing Endoplasmic Reticulum Stress and Inflammation in Cardiomyocytes. BMC Med., 21.","DOI":"10.1186\/s12916-023-02838-2"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jaccao.2025.01.011","article-title":"Personalized Trastuzumab-Induced Cardiac Dysfunction Risk Stratification and Surveillance","volume":"7","author":"Fang","year":"2025","journal-title":"JACC CardioOncology"},{"key":"ref_57","first-page":"14","article-title":"Late Cardiotoxicity Related to HER2-Targeted Cancer Therapy","volume":"10","author":"Senechal","year":"2024","journal-title":"Cardio-Oncol. Lond. Engl."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/OP.23.00494","article-title":"Cardiotoxicity of Agents Used in Patients With Breast Cancer","volume":"20","author":"Zagami","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s12012-024-09876-z","article-title":"Cardiotoxicity of HER2-Targeted Drugs When Combined with Other Drugs: A Systematic and Meta-Analysis of Randomized Controlled Trials","volume":"24","author":"Liu","year":"2024","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11936-024-01067-x","article-title":"Clinical Relevance and Mechanistic Underpinnings of Tyrosine Kinase Inhibitor Associated Cardiotoxicities","volume":"27","author":"Torelli","year":"2025","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Wang, X., Chen, R., Liu, J., Wang, E., and Luo, H. (2025). Liver Injury Related to Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors: A Pharmacovigilance Analysis of the USA FDA Adverse Event Reporting System (FAERS) Database. Expert Opin. Drug Saf., epub ahead of print.","DOI":"10.1080\/14740338.2025.2460449"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Mihalcea, D., Memis, H., Mihaila, S., and Vinereanu, D. (2023). Cardiovascular Toxicity Induced by Vascular Endothelial Growth Factor Inhibitors. Life, 13.","DOI":"10.3390\/life13020366"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","article-title":"Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Gaydarski, L., Petrova, K., Stanchev, S., Pelinkov, D., Iliev, A., Dimitrova, I.N., Kirkov, V., Landzhov, B., and Stamenov, N. (2025). Morphometric and Molecular Interplay in Hypertension-Induced Cardiac Remodeling with an Emphasis on the Potential Therapeutic Implications. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094022"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity Associated with Tyrosine Kinase Inhibitor Sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Deng, Z., Xiao, S., He, Y.-Y., Guo, Y., and Tang, L.-J. (2025). Sorafenib-Induced Cardiovascular Toxicity: A Cause for Concern. Chem. Biol. Interact., 410.","DOI":"10.1016\/j.cbi.2025.111388"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1055\/s-0038-1624566","article-title":"BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?","volume":"2","author":"Haguet","year":"2018","journal-title":"TH Open"},{"key":"ref_68","first-page":"411","article-title":"Imatinib-Induced Decompensated Heart Failure in an Elderly Patient with Chronic Myeloid Leukemia: Case Report and Literature Review","volume":"9","author":"Ran","year":"2012","journal-title":"J. Geriatr. Cardiol. JGC"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.toxrep.2021.05.008","article-title":"Induction of Autophagy Has Protective Roles in Imatinib-Induced Cardiotoxicity","volume":"8","author":"Kobara","year":"2021","journal-title":"Toxicol. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Shaban, N., Kamashev, D., Emelianova, A., and Buzdin, A. (2023). Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications. Cells, 13.","DOI":"10.3390\/cells13010047"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Li, X., Lin, Y., Lin, S., Huang, J., and Ruan, Z. (2024). Advancements in Understanding Cardiotoxicity of EGFR- TKIs in Non-Small Cell Lung Cancer Treatment and Beyond. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1404692"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib Versus Crizotinib in Patients with Advanced ALK-Positive Non\u2013Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study","volume":"42","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Jia, J., Tian, C., Han, W., and Ma, Q. (2025). Real-World Assessment of Thromboembolic Risk Associated with Tamoxifen. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-13585-0"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Muniyan, S., Xi, L., Datta, K., Das, A., Teply, B.A., Batra, S.K., and Kukreja, R.C. (2020). Cardiovascular Risks and Toxicity\u2014The Achilles Heel of Androgen Deprivation Therapy in Prostate Cancer Patients. Biochim. Biophys. Acta Rev. Cancer, 1874.","DOI":"10.1016\/j.bbcan.2020.188383"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed under the Auspices of the ESC Committee for Practice Guidelines: The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","article-title":"Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"10","author":"Taktak","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Li, D., Chai, S., Wang, H., Dong, J., Qin, C., Du, D., Wang, Y., Du, Q., and Liu, S. (2023). Drug-Induced QT Prolongation and Torsade de Pointes: A Real-World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1259611"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40959-023-00160-7","article-title":"Enzalutamide Induced Non-Ischemic Cardiomyopathy. A Case Report and Review of Literature on Anti-Androgen Therapy-Related Cardiovascular Events","volume":"9","author":"Kumar","year":"2023","journal-title":"Cardio-Oncology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40256-024-00709-6","article-title":"Cardiovascular Events Associated with CDK4\/6 Inhibitors: A Safety Meta-Analysis of Randomized Controlled Trials and a Pharmacovigilance Study of the FAERS Database","volume":"25","author":"Zhang","year":"2025","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"100420","DOI":"10.1016\/j.ijcha.2019.100420","article-title":"Cardiotoxicity from Immune Checkpoint Inhibitors","volume":"25","author":"Michel","year":"2019","journal-title":"IJC Heart Vasc."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 Have Opposing Effects on the Response of T Cells to Stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory Mechanisms of PD-1\/PD-L1 in Cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1089\/ars.2016.6930","article-title":"From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview","volume":"30","author":"Tocchetti","year":"2019","journal-title":"Antioxid. Redox Signal."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular Immunotoxicities Associated with Immune Checkpoint Inhibitors: A Safety Meta-Analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Frascaro, F., Bianchi, N., Sanguettoli, F., Marchini, F., Meossi, S., Zanarelli, L., Tonet, E., Serenelli, M., Guardigli, G., and Campo, G. (2023). Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge. J. Clin. Med., 12.","DOI":"10.3390\/jcm12247737"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Alejandre, R., Ruiz-Fern\u00e1ndez, I., and Mart\u00edn, P. (2022). Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis. Cancers, 14.","DOI":"10.3390\/cancers14184494"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jaccao.2021.02.005","article-title":"Takotsubo Cardiomyopathy Associated With Checkpoint Inhibitor Therapy: Endomyocardial Biopsy Provides Pathological Insights to Dual Diseases","volume":"3","author":"Serzan","year":"2021","journal-title":"JACC CardioOncology"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Quagliariello, V., Bisceglia, I., Berretta, M., Iovine, M., Canale, M.L., Maurea, C., Giordano, V., Paccone, A., Inno, A., and Maurea, N. (2023). PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology. Cancers, 15.","DOI":"10.3390\/cancers15051397"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4070\/kcj.2021.0089","article-title":"Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management","volume":"51","author":"Zarifa","year":"2021","journal-title":"Korean Circ. J."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Jo, W., Won, T., Daoud, A., and \u010cih\u00e1kov\u00e1, D. (2024). Immune Checkpoint Inhibitors Associated Cardiovascular Immune-Related Adverse Events. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1340373"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Ciappina, G., Ottaiano, A., Santorsola, M., Esposito, E., De Luca, F., Giorgi, C., Zito, C., Capra, A.P., Carroccio, P., and Maurea, N. (2025). Impact of Proton Pump Inhibitor Use on Progression-Free and Overall Survival in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis of Recent Studies. Cancers, 17.","DOI":"10.3390\/cancers17132228"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review","volume":"5","author":"Georgiopoulos","year":"2023","journal-title":"JACC CardioOncology"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Efentakis, P., Psarakou, G., Varela, A., Papanagnou, E.D., Chatzistefanou, M., Nikolaou, P.-E., Davos, C.H., Gavriatopoulou, M., Trougakos, I.P., and Dimopoulos, M.A. (2021). Elucidating Carfilzomib\u2019s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222010956"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.cardfail.2020.07.006","article-title":"Heart Failure with Carfilzomib in Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials","volume":"27","author":"Rahman","year":"2021","journal-title":"J. Card. Fail."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"134","DOI":"10.37616\/2212-5043.1311","article-title":"Carfilzomib-Induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"34","author":"Buck","year":"2022","journal-title":"J. Saudi Heart Assoc."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Wesley, C.D., Sansonetti, A., Neutel, C.H.G., Kr\u00fcger, D.N., De Meyer, G.R.Y., Martinet, W., and Guns, P.-J. (2024). Short-Term Proteasome Inhibition: Assessment of the Effects of Carfilzomib and Bortezomib on Cardiac Function, Arterial Stiffness, and Vascular Reactivity. Biology, 13.","DOI":"10.3390\/biology13100844"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s44313-024-00004-y","article-title":"Real-World Incidence and Risk Factors of Bortezomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma","volume":"59","author":"Jang","year":"2024","journal-title":"Blood Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-023-00849-z","article-title":"Cardiac Toxicities in Multiple Myeloma: An Updated and a Deeper Look into the Effect of Different Medications and Novel Therapies","volume":"13","author":"Moukalled","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Akram, F., Ali, A.M., Akhtar, M.T., Fatima, T., Shabbir, I., and Ul Haq, I. (2025). The Journey of Antibody-Drug Conjugates for Revolutionizing Cancer Therapy: A Review. Bioorg. Med. Chem., 117.","DOI":"10.1016\/j.bmc.2024.118010"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2019.11.023","article-title":"Trastuzumab Emtansine (T-DM1)-Associated Cardiotoxicity: Pooled Analysis in Advanced HER2-Positive Breast Cancer","volume":"126","author":"Ameye","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"102113","DOI":"10.1016\/j.eclinm.2023.102113","article-title":"Toxicity Profile of Antibody-Drug Conjugates in Breast Cancer: Practical Considerations","volume":"62","author":"Verrazzo","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"DESTINY-Breast03 Trial Investigators. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer","volume":"386","author":"Kim","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall Survival with Sacituzumab Govitecan in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (TROPiCS-02): A Randomised, Open-Label, Multicentre, Phase 3 Trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"De Bousser, E., Callewaert, N., and Festjens, N. (2021). T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy. Cancers, 13.","DOI":"10.3390\/cancers13236067"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","article-title":"Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer","volume":"4","author":"Ganatra","year":"2022","journal-title":"JACC CardioOncology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of Ten-Year Risk of Fatal Cardiovascular Disease in Europe: The SCORE Project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur. Heart J."},{"key":"ref_110","unstructured":"SCORE2 Working Group, and ESC Cardiovascular Risk Collaboration (2021). SCORE2 Risk Prediction Algorithms: New Models to Estimate 10-Year Risk of Cardiovascular Disease in Europe. Eur. Heart J., 42, 2439\u20132454."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"SCORE2-Diabetes Working Group, and The ESC Cardiovascular Risk Collaboration (2023). SCORE2-Diabetes: 10-Year Cardiovascular Risk Estimation in Type 2 Diabetes in Europe. Eur. Heart J., 44, 2544\u20132556.","DOI":"10.1093\/eurheartj\/ehad260"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by Representatives of 10 Societies and by Invited Experts) Developed with the Special Contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2010.08.009","article-title":"The Frailty Syndrome: Definition and Natural History","volume":"27","author":"Xue","year":"2011","journal-title":"Clin. Geriatr. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of Cardiac Disease in Cancer Patients throughout Oncological Treatment: ESMO Consensus Recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jcmg.2022.10.010","article-title":"Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy","volume":"16","author":"Negishi","year":"2023","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11886-022-01692-7","article-title":"Role of Myocardial Strain Imaging in Cancer Therapy\u2013Related Cardiac Dysfunction","volume":"24","author":"Chaganti","year":"2022","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0735-1097(00)00748-8","article-title":"Left Ventricular Dysfunction Predicted by Early Troponin I Release after High-Dose Chemotherapy","volume":"36","author":"Cardinale","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e029574","DOI":"10.1161\/JAHA.123.029574","article-title":"Circulating Cardiovascular Biomarkers in Cancer Therapeutics-Related Cardiotoxicity: Review of Critical Challenges, Solutions, and Future Directions","volume":"12","author":"Murtagh","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s10554-024-03164-1","article-title":"Leveraging the Power of Radiomics to Predict Heart Failure: New Frontiers in Cardio-Oncology","volume":"40","author":"Wang","year":"2024","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the Management of Chronic Coronary Syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.echo.2020.10.002","article-title":"Usefulness of Stress Echocardiography in the Management of Patients Treated with Anticancer Drugs","volume":"34","author":"Novo","year":"2021","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/eurheartj\/ehz851","article-title":"Acute Myocardial Infarction Treatments and Outcomes in 6.5 Million Patients with a Current or Historical Diagnosis of Cancer in the USA","volume":"41","author":"Bharadwaj","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Leo, I., Vidula, M., Bisaccia, G., Procopio, M.C., Licordari, R., Perotto, M., La Vecchia, G., Miaris, N., Bravo, P.E., and Bucciarelli-Ducci, C. (2023). The Role of Advanced Cardiovascular Imaging Modalities in Cardio-Oncology: From Early Detection to Unravelling Mechanisms of Cardiotoxicity. J. Clin. Med., 12.","DOI":"10.3390\/jcm12154945"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of High-Dose Chemotherapy\u2013Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of Cardiac Dysfunction during Adjuvant Breast Cancer Therapy (PRADA): A 2 \u00d7 2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity","volume":"71","author":"Avila","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","article-title":"Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I\u2013Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial","volume":"148","author":"Henriksen","year":"2023","journal-title":"Circulation"},{"key":"ref_133","first-page":"564","article-title":"Efficacy and Harms Associated with Beta-Blockers for Cardiotoxicity in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis","volume":"21","author":"Li","year":"2024","journal-title":"Arch. Med. Sci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"105116","DOI":"10.1016\/j.esmoop.2025.105116","article-title":"Cardioprotection in Patients with Anthracycline-Treated Breast Cancer: Final Analysis from the 2 \u00d7 2 Randomized, Placebo-Controlled, Double-Blind SAFE Trial","volume":"10","author":"Meattini","year":"2025","journal-title":"ESMO Open"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaccao.2024.01.007","article-title":"The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors","volume":"6","author":"Dabour","year":"2024","journal-title":"JACC CardioOncology"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Quagliariello, V., Berretta, M., Bisceglia, I., Giacobbe, I., Iovine, M., Barbato, M., Maurea, C., Canale, M.L., Paccone, A., and Inno, A. (2025). In the Era of Cardiovascular\u2013Kidney\u2013Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy. Cancers, 17.","DOI":"10.3390\/cancers17071169"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Bhalraam, U., Veerni, R.B., Paddock, S., Meng, J., Piepoli, M., L\u00f3pez-Fern\u00e1ndez, T., Tsampasian, V., and Vassiliou, V.S. (2025). Impact of Sodium\u2013Glucose Cotransporter-2 Inhibitors on Heart Failure Outcomes in Cancer Patients and Survivors: A Systematic Review and Meta-Analysis. Eur. J. Prev. Cardiol., epub ahead of print.","DOI":"10.1093\/eurjpc\/zwaf026"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Greco, A., Canale, M.L., Quagliariello, V., Oliva, S., Tedeschi, A., Inno, A., De Biasio, M., Bisceglia, I., Tarantini, L., and Maurea, N. (2025). SGLT2 Inhibitors in Cancer Patients: A Comprehensive Review of Clinical, Biochemical, and Therapeutic Implications in Cardio-Oncology. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26104780"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00003495-199856030-00009","article-title":"Dexrazoxane: A Review of Its Use as a Cardioprotective Agent in Patients Receiving Anthracycline-Based Chemotherapy","volume":"56","author":"Wiseman","year":"1998","journal-title":"Drugs"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jaccao.2024.07.017","article-title":"Cardiovascular Considerations Before Cancer Therapy","volume":"6","author":"Murphy","year":"2024","journal-title":"JACC CardioOncology"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Omland, T., Heck, S.L., Holte, E., Mecinaj Lilleaasen, A., Gynnild, M.N., Fagerland, M.W., Vinje-Jakobsen, V., N\u00e6s, A.-K.L., Blix, E.S., and Larsen, A.I. (2025). Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. Circulation, epub ahead of print.","DOI":"10.1161\/CIRCULATIONAHA.125.076616"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/ehf2.14466","article-title":"Sacubitril\/Valsartan for Cardioprotection in Breast Cancer (MAINSTREAM): Design and Rationale of the Randomized Trial","volume":"10","author":"Tajstra","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e039745","DOI":"10.1161\/JAHA.124.039745","article-title":"Randomized, Placebo-Controlled, Triple-Blind Clinical Trial of Ivabradine for the Prevention of Cardiac Dysfunction During Anthracycline-Based Cancer Therapy","volume":"14","author":"Rizk","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1002\/ejhf.3395","article-title":"RESILIENCE Trial Investigators. Rationale and Design of RESILIENCE: A Prospective Randomized Clinical Trial Evaluating Remote Ischaemic Conditioning for the Prevention of Anthracycline Cardiotoxicity","volume":"26","author":"Kelm","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective Evaluation of the Cardiac Safety of HER2-Targeted Therapies in Patients with HER2-Positive Breast Cancer and Compromised Heart Function: The SAFE-HEaRt Study","volume":"175","author":"Lynce","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pcad.2024.02.002","article-title":"Exercise-Based Cardio-Oncology Rehabilitation for Cardiotoxicity Prevention during Breast Cancer Chemotherapy: The ONCORE Randomized Controlled Trial","volume":"85","year":"2024","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive Heart Failure in Patients Treated with Doxorubicin: A Retrospective Analysis of Three Trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJM199506293322602","article-title":"Female Sex and Higher Drug Dose as Risk Factors for Late Cardiotoxic Effects of Doxorubicin Therapy for Childhood Cancer","volume":"332","author":"Lipshultz","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10549-019-05139-6","article-title":"Cardiac Outcomes of Trastuzumab Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Ejection Fraction","volume":"175","author":"Hussain","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jaccao.2020.12.001","article-title":"Management of Immune Checkpoint Inhibitor\u2013Induced Myocarditis","volume":"3","author":"Thuny","year":"2021","journal-title":"JACC CardioOncology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jacc.2018.02.038","article-title":"Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors","volume":"71","author":"Tocchetti","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular Toxicities of Immune Checkpoint Inhibitors","volume":"74","author":"Ball","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00432-020-03445-x","article-title":"Risk of Lung Cancer and Renin\u2013Angiotensin Blockade: A Concise Review","volume":"147","author":"Rachow","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-024-07263-4","article-title":"Beta-Blocker Use and Breast Cancer Outcomes: A Meta-Analysis","volume":"206","author":"Scott","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/sj.bjc.6605955","article-title":"Inhibition of Renin\u2013Angiotensin System Affects Prognosis of Advanced Pancreatic Cancer Receiving Gemcitabine","volume":"103","author":"Nakai","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1158\/1078-0432.CCR-18-0236","article-title":"Renin\u2013Angiotensin System Inhibitors to Mitigate Cancer Treatment\u2013Related Adverse Events","volume":"24","author":"Pinter","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Khan, S., Huda, B., Bhurka, F., Patnaik, R., and Banerjee, Y. (2025). Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-\u03baB, NLRP3 Inflammasome, and Cytokine Regulatory Axes. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26178429"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","article-title":"Assessment of Dexrazoxane as a Cardioprotectant in Doxorubicin-Treated Children with High-Risk Acute Lymphoblastic Leukaemia: Long-Term Follow-up of a Prospective, Randomised, Multicentre Trial","volume":"11","author":"Lipshultz","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"101688","DOI":"10.1016\/j.xcrm.2024.101688","article-title":"The Effect of SGLT2 Inhibition on Prostate Cancer: Mendelian Randomization and Observational Analysis Using Electronic Healthcare and Cohort Data","volume":"5","author":"Zheng","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10549-021-06192-w","article-title":"Incidence of Cardiotoxicity and Validation of the Heart Failure Association-International Cardio-Oncology Society Risk Stratification Tool in Patients Treated with Trastuzumab for HER2-Positive Early Breast Cancer","volume":"188","author":"Battisti","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immune Checkpoint Inhibitor-Related Adverse Events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1080\/10428194.2018.1533129","article-title":"Risk Factors for the Development of Atrial Fibrillation on Ibrutinib Treatment","volume":"60","author":"Lentz","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2017.1394554","article-title":"Left Atrial Abnormality (LAA) as a Predictor of Ibrutinib-Associated Atrial Fibrillation in Patients with Chronic Lymphocytic Leukemia","volume":"19","author":"Mato","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"108629","DOI":"10.1016\/j.lungcan.2025.108629","article-title":"Prevalence of Osimertinib-Induced Cardiotoxicity in Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis","volume":"205","author":"Gawli","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"suaf083.094","DOI":"10.1093\/eurheartjsupp\/suaf083.094","article-title":"New Generation ALK-Inhibitors Burden in Lung Cancer Patients Cardiovascular Health: Analysis from Real World Data","volume":"27","author":"Aguado","year":"2025","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Jerzak, K.J., Sehdev, S., Boileau, J.-F., Brezden-Masley, C., Califaretti, N., Edwards, S., Gordon, J., Henning, J.-W., LeVasseur, N., and Railton, C. (2025). Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4\/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32080444"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Xia, W., and Khalil, R.A. (2025). Hormone Replacement Therapy and Cardiovascular Health in Postmenopausal Women. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26115078"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Fradin, J., Kim, F.J., Lu-Yao, G.L., Storozynsky, E., and Kelly, W.K. (2023). Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer. Cancers, 15.","DOI":"10.3390\/cancers15082316"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jaccao.2024.09.012","article-title":"Cardiovascular Risk in Prostate Cancer","volume":"6","author":"Leong","year":"2024","journal-title":"JACC CardioOncology"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40959-025-00333-6","article-title":"Investigating Cardiovascular Diseases Related to Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer: Insights from a Nationwide Real-World Study","volume":"11","author":"Zeng","year":"2025","journal-title":"Cardio-Oncology"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/1078155217720006","article-title":"The Clinical Significance of QT Prolongation Associated with Tamoxifen: A Review of the Literature","volume":"24","author":"Fung","year":"2018","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1080\/10428194.2017.1393674","article-title":"Cardio-Oncology in Multiple Myeloma: Is It Time for a Specific Focus?","volume":"59","author":"Mancuso","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ejhf.3102","article-title":"European Society of Cardiology Core Curriculum for cARDIO-ONCOLOGY","volume":"26","author":"Farmakis","year":"2024","journal-title":"Eur. J. Heart Fail."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/9\/1399\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:47:23Z","timestamp":1760035643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/9\/1399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":177,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ph18091399"],"URL":"https:\/\/doi.org\/10.3390\/ph18091399","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}